JP2016193903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016193903A5 JP2016193903A5 JP2016084877A JP2016084877A JP2016193903A5 JP 2016193903 A5 JP2016193903 A5 JP 2016193903A5 JP 2016084877 A JP2016084877 A JP 2016084877A JP 2016084877 A JP2016084877 A JP 2016084877A JP 2016193903 A5 JP2016193903 A5 JP 2016193903A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- chloro
- methyl
- combination
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 15
- -1 3,4-difluorophenyl Chemical group 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- ZLOLCGXDJBXQCN-UHFFFAOYSA-N 5-[[4-[(2,3-dimethylindazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.C1=CC2=C(C)N(C)N=C2C=C1CNC(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 ZLOLCGXDJBXQCN-UHFFFAOYSA-N 0.000 claims 4
- AXTAPYRUEKNRBA-JTQLQIEISA-N n-[(2s)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)OC(C(=O)N[C@H](CN)CC=2C=C(F)C(F)=CC=2)=C1 AXTAPYRUEKNRBA-JTQLQIEISA-N 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical class NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34838510P | 2010-05-26 | 2010-05-26 | |
| US61/348,385 | 2010-05-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013512197A Division JP2013526613A (ja) | 2010-05-26 | 2011-05-25 | 組合せ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016193903A JP2016193903A (ja) | 2016-11-17 |
| JP2016193903A5 true JP2016193903A5 (enExample) | 2017-01-05 |
Family
ID=45004353
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013512197A Withdrawn JP2013526613A (ja) | 2010-05-26 | 2011-05-25 | 組合せ |
| JP2016084877A Pending JP2016193903A (ja) | 2010-05-26 | 2016-04-21 | 組合せ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013512197A Withdrawn JP2013526613A (ja) | 2010-05-26 | 2011-05-25 | 組合せ |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20130237554A1 (enExample) |
| EP (1) | EP2575460A4 (enExample) |
| JP (2) | JP2013526613A (enExample) |
| WO (1) | WO2011150044A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150272950A1 (en) * | 2012-10-22 | 2015-10-01 | Glaxosmithkline Llc | Combination |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1343782B1 (en) * | 2000-12-21 | 2009-05-06 | SmithKline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| WO2010045309A1 (en) * | 2008-10-16 | 2010-04-22 | Glaxosmithkline Llc | Inhibitors of akt activity |
| MY161598A (en) * | 2009-01-30 | 2017-04-28 | Glaxosmithkline Llc | Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
-
2011
- 2011-05-25 US US13/699,103 patent/US20130237554A1/en not_active Abandoned
- 2011-05-25 EP EP11787314.1A patent/EP2575460A4/en not_active Withdrawn
- 2011-05-25 WO PCT/US2011/037881 patent/WO2011150044A1/en not_active Ceased
- 2011-05-25 JP JP2013512197A patent/JP2013526613A/ja not_active Withdrawn
-
2014
- 2014-12-10 US US14/565,691 patent/US20150094283A1/en not_active Abandoned
-
2016
- 2016-04-21 JP JP2016084877A patent/JP2016193903A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015083580A5 (enExample) | ||
| JP2019131596A5 (enExample) | ||
| MX2015011896A (es) | Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia. | |
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| JP2011173928A5 (enExample) | ||
| CN111065639A (zh) | 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 | |
| JP2012502015A5 (enExample) | ||
| JP2013067645A5 (enExample) | ||
| JP2009138003A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| JP2009545600A5 (enExample) | ||
| JP2015511635A5 (enExample) | ||
| JP2018507243A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| JP2014511383A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| JP2017513809A5 (enExample) | ||
| JP2018530578A5 (enExample) | ||
| JP2019530706A5 (enExample) | ||
| JP2015517523A5 (enExample) | ||
| JP2012502103A5 (enExample) | ||
| RU2016116789A (ru) | Комбинация энзалутамида и афурезертиба для лечения рака | |
| JP2019526559A5 (enExample) | ||
| JP2017503846A5 (enExample) | ||
| JP2019518022A5 (enExample) |